Michael Drazer(@michaelwd) 's Twitter Profileg
Michael Drazer

@michaelwd

Physician-scientist @ the intersection of genetics, hematology/oncology, & patient care. Runner. Tweets are my own - no COI. Scholar: https://t.co/AST8hH0Uyk

ID:10056172

linkhttp://thedrazergroup.org calendar_today08-11-2007 05:01:15

4,6K Tweets

983 Followers

662 Following

Pradeep Natarajan(@pnatarajanmd) 's Twitter Profile Photo

Approximately two-thirds of approved drugs over the last decade had human genetics support for the mechanisms of action nature.com/articles/d4157… Nature Reviews Drug Discovery

Approximately two-thirds of approved drugs over the last decade had human genetics support for the mechanisms of action nature.com/articles/d4157… @NatRevDrugDisc
account_circle
Mark Cuban(@mcuban) 's Twitter Profile Photo

Everyone doubted us. Said we couldn't impact an industry that no one trusts. Here we are less than 2 years later announcing we are adding ONE THOUSAND+ new drugs, bringing our total to more than 2,200 !!!
It's time to check again to see if costplusdrugs.com carries your…

account_circle
UChicagoCancerCenter(@UCCancerCenter) 's Twitter Profile Photo

Later today, Tadeusz Kubicki will address two significant questions on mass spectrometry-based assessment in MM patients – the role of MS in response assessment for pts without a high disease burden baseline and the optimal timing of MS assessment.
UChicagoCancerCenter University of Chicago Hematology/Oncology

Later today, Tadeusz Kubicki will address two significant questions on mass spectrometry-based assessment in MM patients – the role of MS in response assessment for pts without a high disease burden baseline and the optimal timing of MS assessment. @UCCancerCenter @UChicagoHemOnc
account_circle
The ASCO Post(@ASCOPost) 's Twitter Profile Photo

From a Small Town in the Rust Belt, Dennis J. Slamon, MD, PhD, Plays a Big Role in Changing the Face of Breast Cancer Treatment ascopost.com/issues/novembe… UCLA Health

account_circle
UChicago Medicine(@UChicagoMed) 's Twitter Profile Photo

The Leapfrog Group gave the University of Chicago Medical Center its 24th consecutive 'A' in patient safety, making it one of just 18 organizations nationwide to receive a straight “A” since the independent industry watchdog began its semiannual review. uchicagomedicine.org/forefront/news…

account_circle
Anand Patel(@Anand_88_Patel) 's Twitter Profile Photo

Day 5 - time to response with Aza-Ven for untreated AML
-most CR/CRis occur in first 2 cycles
-24% of CR/CRis seen on study happened after Cycle 2 (majority during Cycle 3/4)

pubmed.ncbi.nlm.nih.gov/35567776/

Day 5 - time to response with Aza-Ven for untreated AML #leusm -most CR/CRis occur in first 2 cycles -24% of CR/CRis seen on study happened after Cycle 2 (majority during Cycle 3/4) pubmed.ncbi.nlm.nih.gov/35567776/
account_circle
Steve Magness(@stevemagness) 's Twitter Profile Photo

A few years ago, I tracked improvement rates of my college runners and compared it to a whole slew of factors to see if anything correlated.

The most important factor? Did they show up to practice.

Those who missed the fewest days tended to improve the most.

account_circle
ESC & iPSC News(@ESC_iPSC_News) 's Twitter Profile Photo

Drs. Deji Adegunsoye (Deji Adegunsoye, MD, PhD), Natalia Gonzales, and Yoav Gilad (@Y_Gilad) describe how iPSC models address particular challenges presented in various organ systems, and more. The University of Chicago The University of ChicagoMed

📑 bit.ly/3POYqRG

Drs. Deji Adegunsoye (@drdayjee), Natalia Gonzales, and Yoav Gilad (@Y_Gilad) describe how iPSC models address particular challenges presented in various organ systems, and more. @UChicago @UChicagoMed 📑 bit.ly/3POYqRG
account_circle
Michael Drazer(@michaelwd) 's Twitter Profile Photo

onlinelibrary.wiley.com/doi/10.1002/aj…

Great reading that summarizes the recent state of affairs for the most common hereditary hem malignancy syndrome

account_circle